Piper Jaffray analyst William Quirk says CareDx’s Q4 results were driven by strong AlloSure performance and enrollment expansion in the K-OAR study. The analyst views the company’s 2019 revenue guidance as conservative and believes its competitive moat in transplant medicine continues to widen. The stock remains his top small cap idea and Quirk reiterates an Overweight rating on CareDx with a $42 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.